Association of HLA-DR with progressive systemic sclerosis in Japanese. 1994

F Takeuchi, and K Nakano, and H Yamada, and G H Hong, and H Nabeta, and A Yoshida, and K Matsuta, and M Bannai, and K Tokunaga, and K Ito
Department of Medicine and Physical Therapy, Faculty of Medicine, University of Tokyo, Japan.

OBJECTIVE To clarify the contribution of HLA-DR genes to the susceptibility to progressive systemic sclerosis (PSS). METHODS HLA-DR typing was carried out in 36 Japanese patients with PSS, 42 with systemic lupus erythematosus and 104 healthy subjects by polymerase chain reaction (PCR) method using specific primers and by PCR-SSCP (single-standard DNA conformation polymorphism) method. RESULTS A haplotype DRB1*1502-DRB5*0102 was significantly increased in PSS (50.0%, p < 0.00004, pc < 0.001), especially in antitopoisomerase I antibody (a-Scl-70) positive patients (62.5%, p < 0.00003, pc < 0.001) and PSS with diffuse scleroderma (75.0%, p < 0.00001, pc < 0.0001). In addition, DRB1*0802 was also increased in DRB1*1502 negative patients with a-Scl-70, (50.0%, p = 0.033, pc = not significant) and in DRB1*1502 negative patients with diffuse scleroderma (75.0%, p = 0.008, pc = not significant). Thus, 81.3% of a-Scl-70 positive patients, and 93.8% of patients with PSS with diffuse scleroderma showed either HLA-DRB1*1502 or 0802. CONCLUSIONS Our observations show the extreme difference of genetic background of a-Scl-70 positive PSS, with regard to HLA-DR, between Japanese and other ethnic groups including Caucasian and American black persons. The increase in DRB1*1502-DRB5*0102 haplotype supported the hypothesis of Reveille, et al that uncharged polar amino acid residue at position 30 of HLA-DQB1 allele was important for a-Scl-70 positive PSS because close association of the haplotype with DQB1*0601 was well established in Japanese; listed as a hypothetical candidate of PSS susceptible DQB1 allele. DRB1*0802 were also associated with hypothetical candidates of DQ alleles. Furthermore, the sharing of the particular amino acid sequence: valine38 and phenylalanine67-lysine68-glutamic acid69-asparic acid70-arginine71, by DRB5*0102, DRB1*0802 and DR11 (associated with Caucasian PSS) also suggests a contribution of the sequence in HLA-DR molecules to the pathogenesis of PSS according to the shared epitope hypothesis.

UI MeSH Term Description Entries
D007564 Japan A country in eastern Asia, island chain between the North Pacific Ocean and the Sea of Japan, east of the Korean Peninsula. The capital is Tokyo. Bonin Islands
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D008969 Molecular Sequence Data Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories. Sequence Data, Molecular,Molecular Sequencing Data,Data, Molecular Sequence,Data, Molecular Sequencing,Sequencing Data, Molecular
D005260 Female Females
D005838 Genotype The genetic constitution of the individual, comprising the ALLELES present at each GENETIC LOCUS. Genogroup,Genogroups,Genotypes
D006684 HLA-DR Antigens A subclass of HLA-D antigens that consist of alpha and beta chains. The inheritance of HLA-DR antigens differs from that of the HLA-DQ ANTIGENS and HLA-DP ANTIGENS. HLA-DR,Antigens, HLA-DR,HLA DR Antigens
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000483 Alleles Variant forms of the same gene, occupying the same locus on homologous CHROMOSOMES, and governing the variants in production of the same gene product. Allelomorphs,Allele,Allelomorph

Related Publications

F Takeuchi, and K Nakano, and H Yamada, and G H Hong, and H Nabeta, and A Yoshida, and K Matsuta, and M Bannai, and K Tokunaga, and K Ito
March 1982, Tissue antigens,
F Takeuchi, and K Nakano, and H Yamada, and G H Hong, and H Nabeta, and A Yoshida, and K Matsuta, and M Bannai, and K Tokunaga, and K Ito
February 1983, The Journal of rheumatology,
F Takeuchi, and K Nakano, and H Yamada, and G H Hong, and H Nabeta, and A Yoshida, and K Matsuta, and M Bannai, and K Tokunaga, and K Ito
September 1989, Tissue antigens,
F Takeuchi, and K Nakano, and H Yamada, and G H Hong, and H Nabeta, and A Yoshida, and K Matsuta, and M Bannai, and K Tokunaga, and K Ito
April 1978, Tissue antigens,
F Takeuchi, and K Nakano, and H Yamada, and G H Hong, and H Nabeta, and A Yoshida, and K Matsuta, and M Bannai, and K Tokunaga, and K Ito
September 1987, Archives of dermatology,
F Takeuchi, and K Nakano, and H Yamada, and G H Hong, and H Nabeta, and A Yoshida, and K Matsuta, and M Bannai, and K Tokunaga, and K Ito
October 1979, Archives of dermatological research,
F Takeuchi, and K Nakano, and H Yamada, and G H Hong, and H Nabeta, and A Yoshida, and K Matsuta, and M Bannai, and K Tokunaga, and K Ito
January 1981, Immunological communications,
F Takeuchi, and K Nakano, and H Yamada, and G H Hong, and H Nabeta, and A Yoshida, and K Matsuta, and M Bannai, and K Tokunaga, and K Ito
January 1990, Beitrage zur Infusionstherapie = Contributions to infusion therapy,
F Takeuchi, and K Nakano, and H Yamada, and G H Hong, and H Nabeta, and A Yoshida, and K Matsuta, and M Bannai, and K Tokunaga, and K Ito
February 2005, Minerva medica,
F Takeuchi, and K Nakano, and H Yamada, and G H Hong, and H Nabeta, and A Yoshida, and K Matsuta, and M Bannai, and K Tokunaga, and K Ito
April 1979, British medical journal,
Copied contents to your clipboard!